1 comment By Julie Grisham, MS, Science Writer/Editor   |   Monday, July 16, 2012 Memorial Sloan-Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells. read more

Original post:
Launch of Stem Cell Therapy Trial Offers Hope for Patients with Inherited Blood Disorder

Scroll to Top